First Trust Advisors LP Has $1.47 Million Position in Glaukos Corporation (GKOS)

First Trust Advisors LP decreased its position in Glaukos Corporation (NYSE:GKOS) by 50.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,610 shares of the medical instruments supplier’s stock after selling 29,257 shares during the period. First Trust Advisors LP’s holdings in Glaukos Corporation were worth $1,468,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of GKOS. Russell Investments Group Ltd. purchased a new position in Glaukos Corporation during the fourth quarter worth about $5,371,000. State Board of Administration of Florida Retirement System increased its position in Glaukos Corporation by 1.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 7,699 shares of the medical instruments supplier’s stock worth $264,000 after buying an additional 140 shares during the last quarter. State Street Corp increased its position in Glaukos Corporation by 6.9% in the fourth quarter. State Street Corp now owns 281,407 shares of the medical instruments supplier’s stock worth $9,653,000 after buying an additional 18,183 shares during the last quarter. Marshall Wace LLP purchased a new position in Glaukos Corporation during the fourth quarter worth about $1,365,000. Finally, Renaissance Technologies LLC increased its position in Glaukos Corporation by 20.4% in the fourth quarter. Renaissance Technologies LLC now owns 849,000 shares of the medical instruments supplier’s stock worth $29,121,000 after buying an additional 143,800 shares during the last quarter. 88.95% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Shares of Glaukos Corporation (NYSE GKOS) opened at 41.79 on Wednesday. The company has a market cap of $1.43 billion, a P/E ratio of 379.91 and a beta of 1.33. The company’s 50-day moving average price is $40.57 and its 200-day moving average price is $42.05. Glaukos Corporation has a 12 month low of $26.96 and a 12 month high of $52.49.

TRADEMARK VIOLATION WARNING: “First Trust Advisors LP Has $1.47 Million Position in Glaukos Corporation (GKOS)” was published by sleekmoney and is the sole property of of sleekmoney. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://sleekmoney.com/first-trust-advisors-lp-has-1-47-million-position-in-glaukos-corporation-gkos/1926863.html.

GKOS has been the topic of a number of recent research reports. BMO Capital Markets initiated coverage on Glaukos Corporation in a research report on Wednesday, February 22nd. They set an “outperform” rating and a $54.00 price target on the stock. Stifel Nicolaus increased their price target on Glaukos Corporation from $45.00 to $55.00 and gave the stock a “positive” rating in a research report on Tuesday, February 28th. Cantor Fitzgerald raised their price objective on Glaukos Corporation from $45.00 to $54.00 and gave the company an “overweight” rating in a research report on Thursday, March 2nd. TheStreet raised Glaukos Corporation from a “d+” rating to a “c” rating in a research report on Wednesday, March 1st. Finally, Zacks Investment Research downgraded Glaukos Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $48.17.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/first-trust-advisors-lp-has-1-47-million-position-in-glaukos-corporation-gkos/1926863.html

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *